Correlation Between SUA and Prognosis in CHF Patients After Revascularization
SUA and Prognosis in CHF Patients After Revascularization
Abstract
Background: To explore the correlation between serum uric acid (SUA) and prognosis in patients with chronic heart failure (CHF) after revascularization.
Methods: A total of 126 patients with CHF undergoing revascularization [coronary artery intervention (PCI) or coronary artery bypass grafting (CABG)] in the hospital were enrolled as CHF group between December 2021 and October 2022, while 126 healthy controls during the same period were enrolled as healthy control group. The levels of SUA, inflammatory factors and cardiac function in the two groups were detected. The correlation between SUA level and inflammatory factors, cardiac function levels was analyzed. All patients in CHF group were followed up for 6 months to observe prognosis. The differences in the above indexes among patients with different prognosis were compared. The risk factors of prognosis were analyzed by multivariate Logistic regression analysis, and their predictive value for prognosis was evaluated by ROC curves analysis.
Results: SUA, IL-6, TNF-α, NT-proBNP and LVEDD in CHF group were higher than those in healthy control group, while LVEF was lower than that in healthy control group (P<0.05). Among the 126 patients within 6 months after surgery, there were 24 cases (19.05%) with adverse cardiac events (poor prognosis). SUA, IL-6, TNF-α, NT-proBNP and LVEDD in patients with poor prognosis were higher than those with good prognosis, while LVEF was lower than that with good prognosis (P<0.05). SUA level was positively correlated with IL-6, TNF-α, NT-proBNP and LVEDD (r=0.283, 0.292, 0.322, 0.355, P<0.05), while negatively correlated with LVEF (r=-0.368, P<0.05). High level of SUA and low LVEF were independent risk factors of prognosis (OR=1.486, 0.678, P<0.05). Both SUA and LVEF were of prognostic value (AUC=0.805, 0.809, P<0.05).
Conclusion: SUA level is significantly increased in CHF patients, which is an independent risk factor of poor prognosis in CHF patients after revascularization, with high prognostic value.
References
1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022; 24(1): 4-131.
2. Spinar J, Spinarova L, Vitovec J. Pathophysiology, causes and epidemiology of chronic heart failure. Vnitr Lek 2018; 64(9): 834-8.
3. Sun K, Li YY, Jin J. A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair. Signal Transduct Tar 2021; 6(1): 79.
4. Heidecker B, Dagan N, Balicer R, Eriksson U, Rosano G, Coats A, et al. Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 2022; 24(11): 2000-18.
5. Feng Q, Zhao Y, Wang H, Zhao J, Wang X, Shi J. A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients. Front Cardiovasc Med 2022; 9(857922.
6. Freilich M, Arredondo A, Zonnoor SL, McFarlane IM. Elevated Serum Uric Acid and Cardiovascular Disease: A Review and Potential Therapeutic Interventions. Cureus J Med Science 2022; 14(3): e23582.
7. Peng D, Wang SP, Zhao DH, Fan QC, Shu J, Liu JH. [Relationship between hyperuricemia and prognosis in patients with heart failure of coronary heart disease after revascularization]. Zhonghua Yi Xue Za Zhi 2018; 98(17): 1337-41.
8. Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 2012; 22(7): 661-79.
9. Williams SG, Jackson M, Cooke GA, Barker D, Patwala A, Wright DJ, et al. How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic heart failure? Am Heart J 2005; 150(5): 983.
10. Doenst T, Struning C, Moschovas A, Gonzalez-Lopez D, Essa Y, Kirov H, et al. Cardiac surgery 2015 reviewed. Clin Res Cardiol 2016; 105(10): 801-14.
11. Dupuy AM, Kuster N, Bargnoux AS, Aguilhon S, Huet F, Leclercq F, et al. Long term pronostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score. Clin Chem Lab Med 2021; 59(7): 1299-306.
12. Romuk E, Wojciechowska C, Jachec W, Zemla-Woszek A, Momot A, Buczkowska M, et al. Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure. Oxid Med Cell Longev 2019; 2019(9246138.
13. Gopaul VS, Vildhede A, Andersson TB, Erlandsson F, Lee CA, Johansson S, et al. In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters. J Pharmacol Exp Ther 2021; 378(2): 108-23.
14. Sui YB, Zhang KK, Ling LY, Fan R, Liu L. Preclinical study of Shen Qi Li Xin formula in improving the development of chronic heart failure. Histol Histopathol 2022; 37(8): 803-12.
15. Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, et al. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Jama Cardiol 2022; 7(1): 17-25.
16. Xiaojing C, Yanfang L, Yanqing G, Fangfang C. Thymopentin improves cardiac function in older patients with chronic heart failure. Anatol J Cardiol 2017; 17(1): 24-30.
17. Mantovani A, Bonapace S, Dugo C, Beatrice G, Petracca G, Cappelli D, et al. Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure. Int J Cardiol 2022; 353: 127-30.
18. Doehner W, Anker SD, Butler J, Zannad F, Filippatos G, Ferreira JP, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J 2022; 43(36): 3435-46.
Copyright (c) 2023 Bo Miao, Jing Wu, Jiao Wang, Yanxin Li, Yingxiao Da, Dong Wang, Bei Gao
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.